Moderna (MRNA) Current Deferred Revenue (2017 - 2026)

Moderna (MRNA) has 10 years of Current Deferred Revenue data on file, last reported at $256.0 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 104.8% year-over-year to $256.0 million in Q1 2026; TTM through Mar 2026 was $256.0 million, a 104.8% increase from a year earlier, with the FY2025 full-year figure at $99.0 million, down 53.08% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $256.0 million, up from $99.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for MRNA reached as high as $6.1 billion in Q1 2022 and fell as low as $20.0 million in Q2 2024.
• Historically, Current Deferred Revenue has averaged $1.4 billion across 5 years, with a median of $651.0 million in 2023.
• Across the five-year window, Current Deferred Revenue sank 98.85% in 2024 and surged 1315.0% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $2.0 billion in 2022, then sank by 68.06% to $651.0 million in 2023, then sank by 67.59% to $211.0 million in 2024, then tumbled by 53.08% to $99.0 million in 2025, then jumped by 158.59% to $256.0 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $256.0 million in Q1 2026, $99.0 million in Q4 2025, and $320.0 million in Q3 2025.